Pfizer invests in 4D Molecular Therapeutics, a maker of gene delivery vectors

Pfizer ($PFE) announced earlier this month that it is financing the drug discovery efforts of four early-stage companies to the tune of a combined $46 million, including 4D Molecular Therapeutics, the maker of a platform for the delivery of gene vectors. In addition, the Big Pharma gained an option to exclusively license at least one adeno-associated virus for cardiac disease targets as a result of the transaction.

Using its Directed Vector Evolution platform, Emeryville, CA’s, 4D Molecular Therapeutics says it can create a “library” of 100 million gene vectors and find the dozen or so most promising variants for a particular payload’s delivery based on a selection process that’s carried out over the course of a year. Then the normal version of the defective gene that is associated with the targeted disease is inserted into the vector, according to the company website.

Read the article at FierceDrugDelivery

Published On: January 19th, 2016Categories: In the Media
Feel free to share!